To the contrary of other methods like OncoFinder [34] focused on EGFR pathway, our proof of concept experiment was conducted on a selection of nine genes arbitrary chosen because they were described for their role in colon cancer progression and being the target of well-documented drugs. The gene discussed is EGFR; the disease is colonic neoplasm.